Startup Vaccitech Ltd, which developed the vaccine AstraZeneca, is planning an IPO.
A startup, behind the Covid-19 vaccine developed by the University of Oxford and AstraZeneca, is planning an initial public offering.
A startup, behind the Covid-19 vaccine developed by the University of Oxford and AstraZeneca, is planning an initial public offering.
Investors are targeting an IPO valuation of roughly $ 700 million, with the expectation that Vaccitech could grow to a billion-dollar company by the end of the year, according to WSJ.
But there are difficulties due to disagreements with Oxford where exactly the company will place an IPO. Oxford wants to place an IPO in London, while Vaccitech is pushing on the Nasdaq in New York.
Meanwhile, the Covid-19 vaccine has demonstrated the potential of Vaccitech technology to fight hepatitis B, prostate cancer, and human papillomavirus — global health problems with huge markets for effective treatments.
Titan.
Titan.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
